AllSci News
New rare disease biotech Mendra launches with USD 82m Series A
New biopharma Mendra Inc., launched with a USD 82 million Series A financing round. The firm is adopting an in-licensing model to…
IntraBio Plans on Second Rare Disease Indication for Levacetylleucine After Positive Phase 3
IntraBio Inc., announced positive topline data from its pivotal Phase 3 IB1001-303 trial evaluating N-acetyl-L-leucine (levacetylleucine; trade name: Aqneursa) in pediatric and…
University of Virginia Tries CitH3-Targeting Against Sepsis-Induced ARDS
Researchers at the University of Virginia (UVA) have initiated a first-in-human clinical trial of hCitH3-mAb, an antibody designed to interrupt a key…
Insilico, China’s Hygtia Share Global Rights to NRLP3 CNS Drug
Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence, said it entered an exclusive global co-development collaboration with Hygtia Therapeutics…
Infinitopes Secures USD 35m Seed Round to Propel Precision Cancer Vaccines
Infinitopes, a clinical-stage cancer vaccine biotechnology company spun out of the UK’s University of Oxford and supported by Cancer Research UK, said…
Bayer Teams with Vanderbilt to Accelerate CVD and Kidney Innovation
Bayer announced a five-year strategic collaboration with the Nashville, Tennesse-based Vanderbilt University Medical Center (VUMC) to accelerate discovery and development of therapies…
GSK to acquire RAPT Therapeutics for USD 2.2b targeting food allergy drug
GSK entered into a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical focused on immunology and inflammation, in a deal valued…
Moderna, Merck post 5-year data for mRNA cancer vaccine in melanoma
Moderna and Merck reported five-year follow-up data showing sustained recurrence-free survival (RFS) benefits for their personalized mRNA cancer vaccine intismeran autogene when…
Tanabe’s MC1R Agonist Dersimelagon Clears Primary Endpoint in Phase 3 EPP/XLP Trial
Tanabe Pharma America reported positive topline results from the global Phase 3 INSPIRE study of dersimelagon (MT-7117) in adult and adolescent patients…
Think Bioscience Raises $55 Million Series A to Advance Rare Disease Drug Discovery Platform
Think Bioscience Secures USD 55 Million to Advance Rare Disease Pipeline Boulder, Colorado-based Thi...
Corvus Pharma Reports Positive Phase 1 Data for ITKi soquelitinib in Atopic Dermatitis
Corvus Pharmaceuticals announced positive data from a Phase 1 trial assessing pipeline candidate soquelitinib as a treatment for moderate to severe atopic…
AstraZeneca Acquires Remaining China Rights to AbelZeta’s GPC3 Armored CAR-T
AstraZeneca agreed to acquire AbelZeta Pharma’s remaining 50% stake in the China development and commercialization rights to C-CAR031, a glypican-3 (GPC3)-targeted armored…
Exciva Raises EUR 51 Million Series B to Advance Groundbreaking Alzheimer's Therapy
Exciva Secures EUR 51 Million to Advance Alzheimer's Therapy Stockholm-based biotech company Exciva ...
Ocugen’s OCU410 modifier gene therapy shows Phase 2 efficacy in geographic atrophy
Ocugen reported positive preliminary 12-month data from its Phase 2 ArMaDa clinical trial of OCU410 (AAV5-RORA), a modifier gene therapy being developed…
STEAP2-Targeted CAR-T Therapy Enters Phase 1 Trial for Metastatic Prostate Cancer
Novel CAR-T Approach Targets Prostate Cancer's Elusive Molecular Landscape Researche...
The AllSci Brief
Systematic R&D and deal news. Daily.